MedPath

A study to learn more about the effects of a pain relief medicine called methoxyflurane (known as Penthrox(TM)) on pain caused by a minor injury. The effects will be compared to a dummy medicine

Active, not recruiting
Conditions
Acute pain
MedDRA version: 14.0Level: LLTClassification code 10066714Term: Acute painSystem Organ Class: 10018065 - General disorders and administration site conditions
Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
Registration Number
EUCTR2011-000338-12-GB
Lead Sponsor
Medical Developments International Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Recruiting
Sex
All
Target Recruitment
300
Inclusion Criteria

1. Patients 12 years of age or older who are able to give written informed consent or who are accompanied by a parent(s)/legal guardian able to provide written informed consent on their behalf.
2. Evidence of signed and dated informed consent document(s) indicating that the patient (and/or a parent/legal guardian) has been informed of all pertinent aspects of the study.
3. Pain Score = 4 to = 7 as measured using Numerical Rating Scale (NRS) at the time of admission, due to minor trauma.

Are the trial subjects under 18? yes
Number of subjects for this age range: 90
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 200
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 10

Exclusion Criteria

1. Life-threatening condition requiring immediate admission in the Operating Room or Intensive Care Unit.
2. Presence of any other clinical condition(s) that may, in the opinion of the investigator, impact on the patient’s ability to participate in the study, or on the study results, including history of head injury and/or altered consciousness.
3. Unable to provide written informed consent.
4. Known pregnancy or lactation
5. Acute intoxication with drugs or alcohol, based on the judgement of the attending physician.
6. Treatment with any analgesic agent within 5 hours prior to presentation to ED (except diclofenac sodium which is prohibited within 8 hours prior to presentation to ED).
7. Current ongoing use of analgesics for chronic pain.
8. Use of an investigational product within one month prior to presentation to ED.
9. Known personal or familial hypersensitivity to fluorinated anaesthetics.
10. Known personal or familial history of malignant hyperthermia.
11. Clinically significant respiratory depression.
12. Use of methoxyflurane in the previous 4 weeks.
13. Known pre-existing clinically significant renal or hepatic impairment according to the judgement of the clinician.
14. Clinically significant cardiovascular instability.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath